Safe human cell line use needs key safety, identity, and purity testing steps at each cell bank stage. Robust assay plans assure full regulatory compliance, high safety, and product quality.
From iPSC and immune cells to viral vectors, aligned capabilities reduce risk, accelerate timelines, and support scalable, compliant production across clinical and commercial stages.
A CDMO leader highlights two decades of growth, showcasing analytical strength, manufacturing, regulatory support, and integrated services that speed drug development.
Look at how optimized virus banking strengthens manufacturing by enhancing consistency, speeding characterization timelines, and aligning testing strategies with modern regulatory expectations.
An overview of analytical capabilities to boost product quality, meet regulatory expectations, and drive development through phase‑appropriate methods and specialized testing for complex drug programs.
Advanced F-PERT assays provide the sensitivity needed to identify minute levels of reverse transcriptase activity, ensuring regulatory compliance and rapid safety testing.
Integrated human ADME studies streamline the process from 14C synthesis to clinical conduct and final reporting to accelerate your drug development program.
Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.
Real-time monitoring, predictive modeling, and unified data detect variability sooner, improve collaboration, and drive biologics performance from development through commercial production.
Accelerate from development to commercialization with manufacturing solutions. Integrated digital systems and technical advocacy ensure regulatory excellence and rapid batch release.
